secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0001104659-23-092586
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.01, 9.01, 3.02, 4.01, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus completes de-SPAC merger; FDA asks for additional PERIO-01 dose study
------------------------------------------------------------------------------

- Merger closed Aug 10, 2023; MTAC renamed TriSalus Life Sciences, trades on Nasdaq as TLSI and TLSIW.
- Gross proceeds ~$42.9M from trust ($2.7M) and PIPE ($40.15M); ~$9.4M redeemed by MTAC stockholders.
- Sponsor earnout shares subject to price milestones ($15-$30) over 5 years; lock-up 365 days or $12 trigger.
- FDA acknowledged safety of SD-101 with PEDD but requires additional dose-optimization; NDA submission beyond 2025.
- Co plans 40-50 patient study for PERIO-01; Phase 2 initiation targeted in 2023 but subject to change.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-092586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer